| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Although cell-based therapy for severe peripheral vascular diseases is promising, it is needed to be improved to obtain higher therapeutic outcomes for clinical application. In this study, we investigated if combination therapy of cell-based therapeutic angiogenesis with vessel maturing drug was useful for severe hindlimb ischemia, and we also investigated to clarify the mechanism of its action. As a result, this hybrid therapeutic strategy resulted in effective maturation of new vessels by cell-based therapy. This strategy will be expected to become novel and low invasive therapeutic approach for severe hindlimb ischemia.
|
